OX40 ligand expressed by DCs costimulates NKT and CD4⁺ Th cell antitumor immunity in mice
J. Clin. Invest. Jamal Zaini, et al. 117:3330 doi:10.1172/JCI32693 [Go to this article.]

Figure 4
IFN-γ production of NKT cells in tumors treated with AdOX40L-modified DCs. (A) IFN-γ levels in tumors. Five days after intratumoral injection of AdOX40L-modified DCs to 8-day established B16-F10 tumors in wild-type or NKT cell^–/– mice, the tumors were dissected, and the IFN-γ levels in the tumor homogenates were measured by ELISA. Tumor-bearing mice treated with AdNull-modified DCs as well as those without any treatment were used as controls. (B) IFN-γ⁺CD1d/α-GalCer dimer⁺ cells in tumors. A single-cell suspension was prepared from the B16-F10 tumors treated as in A, and the IFN-γ⁺ cells were analyzed for the CD1d/α-GalCer dimer binding by flow cytometry. Overlay (filled) histogram depicts IFN-γ⁺ cells stained without dimer. The percentages of CD1d/α-GalCer dimer⁺ cells above control staining are shown in each panel.